Drugs / AS1411
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00881244 | Sep 2003 → Jun 2006 | cancer | Antisoma Research | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01034410 | Jan 2010 → Jan 2011 | acute myeloid leukemia | Antisoma Research | Terminated | No outcome recorded |
| Phase 2 | NCT00740441 | Aug 2008 → Sep 2009 | renal cell carcinoma | Antisoma Research | Unknown | No outcome recorded |
| Phase 2 | NCT00512083 | Jul 2007 → Apr 2009 | acute myeloid leukemia | Antisoma Research | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AS1411 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01034410 ↗ |
| Modality | Aptamer | “AS1411, a DNA aptamer targeting nucleolin (a protein which is overexpressed in many tumor types), was evaluated” PMID 24242861 ↗ Nov 2013 |
| Route | Intravenous | “AS1411 IV administration” NCT00512083 ↗ |